Free tool
FAERS Monitor: Tybost
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203094 or its brand name (Tybost, Cobicistat). Reports on generic versions are filed under their own applications.
Reports
621
Serious
582
94% of reports
Hospitalization
194
Death reported
64
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug interaction181
- cushing^s syndrome60
- foetal exposure during pregnancy48
- immune reconstitution inflammatory syndrome38
- serotonin syndrome36
- adrenal insufficiency32
- off label use29
- anxiety26
- drug ineffective25
- pain25
- virologic failure24
- emotional distress22
- acute kidney injury20
- anhedonia20
- depression20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 5 |
| 2014 | 13 |
| 2015 | 11 |
| 2016 | 37 |
| 2017 | 33 |
| 2018 | 44 |
| 2019 | 83 |
| 2020 | 82 |
| 2021 | 41 |
| 2022 | 80 |
| 2023 | 61 |
| 2024 | 60 |
| 2025 | 50 |
| 2026 | 18 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,538 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| immune reconstitution inflammatory syndromeSignal | 38 | 260.3 | 191.0 | 9,486 |
| virologic failureSignal | 24 | 151.8 | 102.5 | 3,432 |
| adrenal insufficiencySignal | 32 | 89.5 | 63.9 | 2,708 |
| serotonin syndromeSignal | 36 | 63.6 | 46.3 | 2,154 |
| drug interactionSignal | 181 | 38.7 | 34.2 | 6,650 |
| anhedoniaSignal | 20 | 25.8 | 16.8 | 452 |
| foetal exposure during pregnancySignal | 48 | 20.0 | 15.2 | 851 |
| emotional distressSignal | 22 | 6.2 | 4.1 | 90 |
| acute kidney injurySignal | 20 | 4.4 | 2.9 | 50 |
| anxietySignal | 26 | 3.1 | 2.1 | 35 |
| depressionSignal | 20 | 3.0 | 1.9 | 25 |
| pain | 25 | 1.4 | 0.9 | 2 |
| off label use | 29 | 1.1 | 0.8 | 0 |
| drug ineffective | 25 | 0.6 | 0.4 | 5 |
| cushing^s syndrome | 60 | 0.0 | 0.0 | 2,000,402 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.